AliveCor Inc. announced the launch of a cloud-based electrocardiogram (ECG) analytics program with Preventice Solutions. Using AliveCor’s proprietary algorithms in this pilot program, Preventice Solutions intends to improve its internal workflow by reading the most critical ECGs first.

catheter ablation, Afib, Amiodarone, Luigi Di Biase, ACC, heart failure

Patients with heart failure and atrial fibrillation were less likely to experience death, hospitalization or recurrent Afib with catheter ablation than with a heart rhythm-regulating drug, according to a new study. Catheter ablation was most successful in procedures where ablation was required in other areas in addition to the pulmonary vein. The study was presented at the American College of Cardiology’s 64th Annual Scientific Session.

BioTelemetry Inc. has reached a settlement agreement with the U.S. Department of Justice related to allegations that BioTelemetry encouraged physicians to use two non-specified diagnosis codes to ensure coverage of mobile cardiac telemetry. Per the agreement, BioTelemetry will pay $6.4 million to the Department of Justice, which was reflected in the Company's 2014 financial statements.

The Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions will take place May 6-9 in San Diego, California. SCAI 2015 will deliver updates affecting the invasive/interventional cardiovascular field, including late-breaking clinical trials; keynote addresses; and practice-relevant education for diagnosing and treating patients with congenital, coronary, peripheral and structural heart disease.

Edwards Lifesciences Corp. announced that chairman and CEO Michael A. Mussallem served as an invited expert panelist on behalf of the Advanced Medical Technology Association (AdvaMed) at the United States Senate Health, Education, Labor and Pensions Committee hearing on "Continuing America's Leadership: Advancing Research and Development for Patients."

TAVR, transcatheter heart valves, GlobalData, TMVR

Research and consulting firm GlobalData reported that the global market value for transcatheter heart valves will expand at a Compound Annual Growth Rate (CAGR) of 19.7 percent through 2020, reaching an approximate value of $3.02 billion.

The 6th Annual Vitals Index revealed that the national average for wait times for doctors dropped to 19 minutes and 16 seconds, a full one-minute shorter than the 2014 wait time average.

The biggest technology news coming out of the 2015 American College of Cardiology (ACC) annual scientific sessions involved the overwhelmingly positive late-breaking trial data for transcatheter aortic and mitral valve repair. ACC dedicated an entire day of late-breaking trial presentations to this new technology, highlighting its importance in how cardiology will be changing in the coming years, moving from invasive surgical repairs to minimally invasive percutaneous therapies.

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack or stroke, with the benefit appearing to accrue for nearly three years, according to a study presented at the 2015 American College of Cardiology (ACC) Annual Scientific Session.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now